Company Filing History:
2 out of 2 
2 out of 2 Years Active: 2016-2017
Title: Weiguang Li: Innovator in Inflammatory Bowel Disease Treatment
Introduction
Weiguang Li is a notable inventor based in Beijing, China. He has made significant contributions to the field of medicine, particularly in the treatment of inflammatory bowel disease (IBD). With a total of 2 patents, his work focuses on innovative therapeutic solutions that aim to improve patient outcomes.
Latest Patents
Li's latest patents include groundbreaking applications of the CZLC31 protein and its derivatives. The first patent introduces the application of derivative CZLC31 in the preparation of medicines for preventing and treating IBD. This invention highlights the protein's effectiveness in managing conditions such as ulcerative colitis (UC) and Crohn's disease (CD). The invention emphasizes that the CZLC331 protein can significantly reduce the adverse effects associated with existing IBD treatments, thereby improving the quality of life for patients.
The second patent also revolves around the application of flagellin derivative CZLC31 for similar therapeutic purposes. This invention reiterates the protein's preventive and therapeutic benefits for IBD, showcasing its potential to alleviate patient pain and enhance rehabilitation outcomes. The broad application prospects of this drug position it as a vital player in the future of IBD treatment.
Career Highlights
Weiguang Li has worked with esteemed organizations such as Suzhou Sciscape Biomedicine Science & Technology Co. Ltd. and the Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China. His experience in these institutions has contributed to his expertise in biomedical research and innovation.
Collaborations
Li has collaborated with notable colleagues, including Chenggang Zhang and Junhuai Li. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the medical field.
Conclusion
Weiguang Li's contributions to the treatment of inflammatory bowel disease through his innovative patents demonstrate his commitment to improving patient care. His work not only addresses critical medical challenges but also paves the way for future advancements in therapeutic solutions.